Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAventyn, Inc.
About this trial
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.
Eligibility criteria
Qualifiers
Men and women over 18 years of age are included
Diabetes with A1C of 7.5 or higher;
or Heart disease with stent placement;
or Coronary Artery Bypass Graft (CABG) in the last 12 months;
Disqualifiers
Those subjects who are not willing to sign an informed consent
Trial design
Treatments tested in this trial
- CHAPERONE AI
- CKMiq AI
- Quality of Life
Treatment groups
300 Participants
are divided into 2 treatment groupsLocations
5Sweden
Karolinska University Hospital Stockholm Sweden
United States
Fountains Family Care85248, ChandlerArizona, United States
Gilbert Cardiology85297, GilbertArizona, United States
Arizona Heart Foundation85014, PhoenixArizona, United States
Sponsors and collaborators
Aventyn, Inc.
Lead sponsor
Dignity Health
Collaborator
Arizona Heart Foundation
Collaborator
Arizona State University
Collaborator
University of Arizona
Collaborator
University of Phoenix College of Nursing
Collaborator
Creighton School of Medicine, Phoenix Arizona
Collaborator
Karolinska University Hospital
Collaborator
Partnership for Economic Innovation Arizona
Collaborator
Kanasu Labs
Collaborator
Intel Corporation
Collaborator
Source ClinicalTrials.gov